TGFB1 and breast carcinoma: Treatment with SB525334 (TGF-β type I receptor inhibitor) or chemerin rescued the expression of E-cadherin detected along the plasma membranes and inhibited the translocation of β-catenin and SMAD2/3 into the nucleus in TGF-β-treated breast cancer cells.